MK0767 Added to Insulin Therapy in Patients With Type 2 Diabetes (0767-030)

Merck Sharp & Dohme (MSD)

Status and phase: Terminated; Phase 3

Conditions: Diabetes Mellitus, Type 2

Treatments: Drug: MK0767

Study type: Interventional

Funder types: Industry

Identifiers

NCT00543816

MK-0767-030

0767-030

2007_628

Details and patient eligibility

About

This study will look to see if MK0767 works better than placebo in controlling blood sugar in patients with Type 2 Diabetes who are taking insulin but do not have adequate control of their blood sugar.

This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

Enrollment: 100 patients

Sex: All

Ages: 21+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Type 2 Diabetes with inadequate glycemic control
• Patient is on stable insulin therapy alone or with one oral antidiabetic agent
• Male or non-pregnant female 21 years or older
• Total daily dose of insulin must be less than or equal to 30 but not greater than or equal to 200 units/day

Exclusion criteria

• Have a history of type 1 diabetes mellitus
• History of ketoacidosis who are being treated with insulin
• Are taking 2 or more antidiabetic agents in combination with insulin

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind